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Abstract
Background: Little is known on the characteristics of patients diagnosed with idiopathic pulmonary fibrosis (IPF) in
Spain. We aimed to characterize the demographic and clinical profile of IPF patients included in the IPF National
Registry of the Spanish Respiratory Society (SEPAR).
Methods: This is a prospective, observational, multicentre and nationwide study that involved 608 IPF patients
included in the SEPAR IPF Registry up to June 27th, 2017, and who received any treatment for their disease. IPF
patients were predominantly males, ex-smokers, and aged in their 70s, similar to other registries.
Results: Upon inclusion, mean ± SD predicted forced vital capacity was 77.6% ± 19.4, diffusing capacity for carbon
monoxide was 48.5% ± 17.7, and the 6-min walk distance was 423.5 m ± 110.4. The diagnosis was mainly established
on results from the high-resolution computed tomography in the proper clinical context (55.0% of patients), while
21.2% of patients required invasive procedures (surgical lung biopsy) for definitive diagnosis. Anti-fibrotic treatment
was prescribed in 69.4% of cases, 51.5% pirfenidone and 17.9% nintedanib, overall with a good safety profile.
Conclusions: The SEPAR IPF Registry should help to further characterize current characteristics and future trends of IPF
patients in Spain and compare/pool them with other registries and cohorts.
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Background
Idiopathic pulmonary fibrosis (IPF) is a fatal, chronic
fibrosing interstitial pneumonia, of unknown aeti-
ology, which affects primarily adults older than 50
[1–3]. Although there is a great variability in the oc-
currence of IPF, possibly due to geographic and
demographic differences, the most reliable data esti-
mate a prevalence ranging approximately 13–20 per
100,000 inhabitants in women and men, respectively
[4]. The IPF mean survival ranges between 2 and 4
years from diagnosis for patients not receiving anti-
fibrotic treatment [5]. Some factors have been identi-
fied to be associated with poorer prognosis and
shorter survival time, such as older age, smoking sta-
tus (smokers and ex-smokers), lower body mass
index, more impaired pulmonary function (mainly on
forced vital capacity, FVC, total lung capacity, TLC,
and diffusing capacity for carbon monoxide, DLCO),
radiological findings (usual interstitial pneumonia,
UIP), a pattern or greater extent of fibrosis, and the
development of acute exacerbations or comorbidities,
especially pulmonary hypertension and emphysema
[6–10]. The diagnosis of IPF requires the collabor-
ation of a multidisciplinary team of specialists to inte-
grate and interpret complex clinical information [11,
12]. Anti-fibrotic treatments for IPF aim to slow
down the disease progression and increase the sur-
vival time [13, 14]. To date, there are two effective
disease-modifying therapies, pirfenidone and ninteda-
nib [2]. Besides the performance of clinical trials for
investigating the efficacy and safety of novel drugs,
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observational studies from routine clinical practice are
also required for understanding the natural course of
the disease, and identifying differential patterns of
diagnosis and treatments [15–17]. Several national
IPF registries have been created worldwide; however
published results are still scarce [18–24]. The Spanish
Society of Pneumology and Thoracic Surgery
(‘Sociedad Española de Neumología y Cirugía Torá-
cica’, SEPAR) started in 2012 a National IPF Registry
aimed to know the clinical characteristics of IPF pa-
tients, procedures for diagnosis, and the evolution of
patients in Spain. The primary objective of the
present study was to characterize the demographic
and clinical profile of IPF patients included in the
SEPAR IPF National Registry, regardless of any re-
ceived treatment.
Methods
Study design
This prospective, observational, multicentre and nation-
wide study involved patients with IPF who were included
in the SEPAR IPF National Registry and received any
treatment for their disease. A total of 28 public hospitals,
widely distributed through Spain, participated in the
study by including patients in the Registry. Patients were
eligible if confirmed diagnosis of IPF. The diagnosis of
IPF was based on criteria from international clinical
guidelines [10]. Those cases receiving pirfenidone for at
least 12 months were analysed to evaluate treatment ef-
fects in the real-world clinical practice. Procedures were
in accordance with guidelines established in the Declar-
ation of Helsinki, and with the principles of Good Clin-
ical Practices. We have followed and endorsed the
Strengthening the Reporting of Observational studies in
Epidemiology (STROBE) guidance for reporting observa-
tional evidence [24]. Each participating hospital obtained
the ethic approval from the Human Research Ethics
Committee.
Data collection and statistical analysis
All pulmonologists from SEPAR were invited to partici-
pate in this IPF Registry. They collected the information
during routine visits, and uploaded data to the SEPAR
website, up to June 27th 2017 [25]. The first patient in-
cluded was in January 10th, 2012. Database lock oc-
curred in October 5th, 2017. Continuous variables are
expressed as the mean, standard deviation (SD), whereas
categorical variables as absolute and relative frequencies
(%). Median survival time was determined including the
corresponding 95% confidence interval (95% CI). Signifi-
cant prognostic factors associated with mortality were identi-
fied by using a backward Cox regression analysis (Hazard
ratio, HR). Survival was analysed by Kaplan-Meier method-
ology. Variables included in the analysis were: age, FVC (%
of predicted) at diagnosis, DLCO at diagnosis, anti-fibrotic
treatment (yes/no), proton-pump inhibitors (yes/no), re-
ported comorbidities such as pulmonary emphysema (yes/
no) or pulmonary hypertension (yes/no), and smoking
habits. The patient comorbidities were reported by each par-
ticipant and the Charlson comorbidity index was calculated
after including the data in the Registry. All statistical proce-
dures were performed by using SAS 9.4 software.
Results
From 713 patients included in the SEPAR IPF National
Registry, 105 were finally excluded (Fig. 1). Therefore,
the number of patients evaluable for the primary end-
point was 608. Regarding participating centres, 18 were
interstitial lung disease (ILD) academic centres, and 10
non-ILD academic centres [26].
Registry patients
Demographics
Patients were predominantly male (80.8%), with a mean age
of 70.2 years (SD 9.2), a mean body mass index of 28.2 kg/
m2 (SD 4.2), and ex-smokers (63.7%). Demographic and clin-
ical characteristics of patients are shown in Table 1. Time
from the onset of symptoms to diagnosis was 20.4months
(SD 21.4).
Comorbidities
The Charlson comorbidity index was 3.5 (SD 1.7). Dia-
betes mellitus with no target organ damage (15.8% of
patients), chronic respiratory disease (15.6%), arterial
hypertension (14%), gastroesophageal reflux (12.8%),
pulmonary emphysema (12.1%), and coronary artery dis-
ease (8.6%) were the most frequent comorbidities.
IPF characteristics
Regarding symptoms or signs indicative of IPF at the
time of diagnosis, 89.6% of patients had inspiratory
bibasilar crackles, 84.7% dyspnoea (mainly grade 2 or
1), 62.8% non-productive cough, and 29.4% digital
clubbing. The mean FVC was 77.6% of predicted (SD
19.4), mean DLCO was 48.5% of predicted (SD 17.7),
mean TLC was 72.5% of predicted (SD 16.5), and the
6-min walk distance (6MWD) was 423.5 m (SD 110.4;
Table 2).
Diagnostic procedures
The high-resolution computed tomography (HRCT) was
the most frequent procedure performed at diagnosis
(99.2% of patients), followed by pulmonary function tests
(98.3%), autoimmune serology (91.8%), chest radiog-
raphy (81.7%), and the 6-min walking test (71.2%). The
confident radiological UIP pattern was found in 65.4% of
cases (Table 3). The definitive diagnosis of IPF was
established in the 55% of cases by the results of the
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HRCT in the proper clinical context (after evaluation by
ILD clinical and radiological experts). A multidisciplin-
ary discussion with the whole ILD committee was re-
quired for definitive IPF diagnosis in 45% of cases; 21.2%
of patients that underwent surgical lung biopsy (surgical
or transbronchial cryobiopsy), and 23.8% without biopsy.
Treatment approach
Patients were receiving pirfenidone (51.5%) or nintedanib
(17.9%) as disease-modifying therapies for IPF at inclusion
in the Registry. Main concurrent treatments were: proton-
pump inhibitors (68.9%), oxygen therapy (21.5%), or oral
corticosteroids (17.8%). From 30.6% of cases not anti-
fibrotic treatment: 8.5% were > 85 years, 43.5% presented
an FVC > 80%. Of those treated patients, 24.7% experi-
enced at least one adverse event, such as gastrointestinal
discomfort (14.0% of patients), anorexia/weight loss (5.9%),
alteration of liver enzymes (3.3%), and photosensitivity
(2.6%). The adverse event (AE) was the reason for discon-
tinuing the treatment in 27 patients (4.4% of total): pirfeni-
done (n = 15), nintedanib (n = 11), or oral corticosteroids
(n = 1). Recommended non-pharmacological treatment
such as rehabilitation and lung transplant were performed
in 10.1 and 3.1%, respectively.
Survival
A total of 108 patients (17.8%) died during the follow-
up, 88 male (81.48%) and 20 females (18.51%) (HR 1.5;
95% 0.94–2.3, p = 0.092) (Fig. 2a). The causes of death
were: disease progression (45.4%), disease exacerbation
(15.7%), lung cancer (5.6%), post-lung transplantation
(3.7%), and others /unknown (29.6%). The median sur-
vival time was 5.8 years (95 CI 4.8–6.6) since diagnosis.
The DLCO at diagnosis was the only prognostic factor as-
sociated with mortality (HR 0.609; 95%CI 0.525–0.706).
A patient had 39.1% lower risk of death per 10 units of
DLCO (%) increased.
Patients receiving pirfenidone
A total of 231 patients received pirfenidone for at least
12 months. Patients were predominantly male (79.7%),
with a mean age of 68.2 years (SD 9.2), and ex-smokers
(68.4%; Table 4). In these patients, the definitive diagno-
sis was established by results of the HRCT (52.2%), after
Fig. 1 Flowchart of patients. 608 patients were evaluable for the main objective of the study (IPF Spanish patient characterization). 231 patients
that received pirfenidone for at least 12 months were analysed to evaluate safety of treatment and clinical features of this subgroup of cases
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undergoing the surgical lung biopsy (27.6%), or by multi-
disciplinary discussion (20.2%).
Changes in IPF characteristics
Patients receiving pirfenidone showed a stable lung
function in FVC (71.5% of predicted, SD 16.7) and
DLCO (47.2% of predicted, SD 17.6) after 12 months
of treatment (compared with baseline, 74.1% of pre-
dicted, SD 15.5 for FVC; and 47.4% of predicted, SD
16.9 for DLCO). The mean 6MWT distance was simi-
lar after 12 months of treatment (429.9 m, SD 117.4)
than at baseline (425.5 m, SD 114.7).
Safety profile
Of patients receiving pirfenidone, 23.4% experienced at
least one adverse event (Table 4). Of 231 patients receiv-
ing pirfenidone, 15.2% had to modify the treatment dur-
ing the follow-up period. Reasons of treatment
modification (dose reduction n = 10, discontinuing the
treatment n = 9) were as follows: clinical worsening of
disease (3.5%), AEs (2.2%) and requiring concomitant
medications (1.3%).
Survival
Eight patients receiving pirfenidone (3.5%) died during
the first 12-month period of treatment. A total of 55
Table 1 Demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis
N available Total
Gender (male/female), n 608 491 (80.8)/ 117 (19.2)
Age, mean years (SD) 608 70.2 (9.2)
Weight mean kg (SD) a 549 77.0 (14.2)
Height mean cm (SD) b 547 165.0 (8.9)
Body mass index, Kg/m2 (SD) b 547 28.2 (4.2)
Smoking habits, n (%) 608
Never-smoker 164 (27.3)
Ex-smoker 382 (63.7)
Smoker 54 (9.0)
Charlson comorbidity index, mean (SD) c 563 3.5 (1.7)
Estimated 10-year survival, mean % (SD) d 607 59.8 (29.6)
Occupational exposure to, n (%) 608
Inorganic particles 131 (23.2)
Organic particles 120 (21.4)
Potentially harmful aerosols 63 (11.3)
Family history, n (%) 608
IPF 57 (9.7)
Other DILD 23 (4.2)
Time from diagnosis to inclusion in the registry, mean years (SD) 608 1.7 (2.2)
Months from the onset of symptoms to diagnosis, mean (SD) e 547 20.4 (21.4)
Main comorbidities, n (%) 608
Diabetes mellitus with no target organ damage 89 (15.8)
Other chronic pulmonary disease 88 (15.6)
Gastroesophageal reflux 74 (12.8)
Pulmonary emphysema 70 (12.1)
Coronary artery disease 50 (8.6)
Myocardial infarction 46 (8.2)
Pulmonary hypertension 36 (6.2)
Malignancies 30 (5.3)
Sleep apnoea-hypopnea syndrome 29 (5.0)
Peripheral vascular disease 24 (4.3)
SD standard deviation, IPF idiopathic pulmonary fibrosis, DILD diffuse interstitial lung disease. Calculated over: a 549 patients, b 547 patients, c 563 patients, d 607
patients, e 547 patients
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patients (23.8%) died during the follow-up. 87.3%
were male and 12.7% female (Fig. 2b). The median
survival time was 5.8 years (95 CI 4.2–9.2) since diag-
nosis (Fig. 2c). Causes of death were: disease progres-
sion (32 patients, 58.2%), disease exacerbation (8
patients, 14.5%), lung cancer (5 patients, 9.1%), and
others /unknown (10 patients, 18.2%).
Discussion
Limited information is available about the demographic
and clinical profile of IPF patients in Spain, the diagnostic
decision-making, and treatments for IPF in real-life set-
ting. To our knowledge, data from 7 national IPF registries
have published so far [18–24]. While some IPF features
are common in all countries such as male predominance,
mean age, and smoking history, other demographic and
clinical data differ from other registries, especially mean
FVC, DLCO and 6MWD at inclusion, or the basis for the
final diagnosis (Table 5). Probably, the heterogeneity of
data among registries would depend on the different
methodology and type of centres. Some authors have thus
suggested creating a global IPF registry, or connecting
current IPF networks, such as the ARIANE-IPF pan-
European IPF registry and biobank [28]. The goal of the
present study is to publish for the first time results from
the Spanish IPF national registry on the profile of patients
with IPF in routine clinical practice.
In agreement with international consensus, in most
cases the diagnosis was based on typical HRCT images
in the clinical context [11, 12, 29–32]. 45% of cases re-
quired a case-discussion by the whole ILD multidiscip-
linary committee. Walsh and colleagues showed a good
agreement for the IPF diagnosis between pulmonolo-
gists, independently of the type of centre (academic or
non-academic centres), with higher concordance in
those cases with ILD MDT availability (32). The Fleisch-
ner Society recently stated that a confident IPF diagnosis
can be achieved when HRCT shows a typical or probable
UIP pattern [12]. On the other hand, the MDT discus-
sion of each potential IPF case with probable, possible or
inconsistent UIP pattern is recommended in the updated
IPF guideline (11). Once made the diagnosis of IPF, the
treatment with anti-fibrotics should start as soon as
possible [33]. In our study 51.5 and 17.9% of the partici-
pants were receiving pirfenidone or nintedanib, respect-
ively. Besides this, some pulmonologists seem reluctant
to treat patients with “mild” or “stable” disease, and thus
they perform a wait and see approach, probably for
avoiding potential AEs or due to misunderstanding by
pulmonologists [34, 35]. An international survey re-
vealed that only 40% of patients with a confirmed diag-
nosis will receive anti-fibrotic treatment; and among
Table 2 Clinical and laboratory findings of patients with
idiopathic pulmonary fibrosis
n available Total
Pulmonary function tests, mean (SD)
FVC, L 580 2.6 (0.8)
FVC, % of predicted 584 77.6 (19.4)
FEV1, L 574 2.1 (0.6)
FEV1, % of predicted 578 81.8 (19.6)
FEV1/FVC, % of predicted 569 82.0 (9.5)
Total lung capacity, L 416 4.4 (1.2)
Total lung capacity, % of predicted 451 72.5 (16.5)
DLCO adjusted for haemoglobin 285 8.8 (14.2)
DLCO, % of predicted 523 48.5 (17.7)
kCO, % of predicted 458 74.9 (23.1)
PaO2, mmHg 215 68.0 (15.8)
PaCO2, mmHg 213 38.6 (6.7)
DA-aO2, mmHg 213 77.2 (15.7)
Oxygen saturation, % 416 94.9 (2.4)
6-min walking test, mean (SD)
Distance, m 419 423.5 (110.4)
Autoantibodies in serum, n (%) 500 28 (5,6)
Anti-dsDNA 482 27 (5.6)
Rheumatoid factor 500 18 (3.6)
ANCAs 500 10 (2.0)
Anti-Sm 437 7 (1.6)
Anti-SCL-70 429 3 (0.7)
SD standard deviation, FVC forced vital capacity, FEV1 forced expiratory volume
in 1 s, DLCO diffusing capacity for carbon monoxide, kCO carbon monoxide
transfer coefficient, PaO2 partial pressure of arterial oxygen, PaCO2 partial
pressure of arterial carbon dioxide, DA-aO2 difference in the alveolar-to-arterial
O2 gradient, anti-dsDNA anti-double-stranded DNA, ANCAs anti-neutrophil
cytoplasmic antibodies
Table 3 Results of different diagnostic procedures regarding usual interstitial pneumonia (UIP) pattern
Confident UIP pattern Probable UIP pattern Indeterminate UIP pattern Alternative or no suggestive
HRCT 65.4 (391/598) 25.3 (151/598) 7.7 (46/598) 1.6 (10/598)
Possible UIP Probably UIP
Surgical lung biopsy 85.5 (135/158) 8.2 (13/158) 2.5 (4/158) 0.6 (1/158)
Lung cryobiopsy 51.2 (21/41) 14.6 (6/41) 9.8 (4/41) 12.2 (5/41)
HRCT high-resolution computed tomography, UIP usual interstitial pneumonia
Data are presented as percentage of patients (n/ N available)
Fernández-Fabrellas et al. Respiratory Research          (2019) 20:127 Page 5 of 10
untreated patients, 45% receive no treatment at all [34].
Another survey has recently shown that pulmonologists
who initiated the anti-fibrotic treatment after more than
4months of patient’s diagnosis (46% of total) saw fewer
patients and had less confidence in the treatment than
those who initiated it in ≤4 months [36]. On the other
hand, patients with IPF have a higher risk of developing
comorbidities [37]. In our study, 12.8% of our patients
had gastro-oesophageal reflux, 12.1% pulmonary emphy-
sema, 8.6% coronary artery disease, and 6.2% pulmonary
hypertension. It is interesting to note the low number of
cases of gastro-oesophageal reflux or cardiovascular dis-
ease, compared with literature. Previous studies have
shown a prevalence of 87 and 66% for gastro-
oesophageal reflux and coronary artery disease in IPF,
respectively [38, 39]. Some studies have demonstrated an
association between decreased disease progression and
longer survival time and the treatment of gastro-
oesophageal reflux with antacid [40]; whereas other have
not so [41]. In our study, the high percentage of patients
receiving proton-pump inhibitors (65.3%) does contrast
with the low percentage of patients diagnosed with
symptomatic gastro-oesophageal reflux. One explanation
is that these treatments were prescribed at the time of
IPF diagnosis, before the beginning of the “anti-fibrotic”
era. Furthermore, in our study, approximately one in ten
patients had family history of IPF, and 55.9% of pa-
tients experienced occupational exposures (inorganic,
organic particles, or potentially harmful aerosols). In
this line, diverse studies have reported an increased
risk of UIP in workers exposed to fumes, metal or or-
ganic dust [42, 43].
We aimed to describe pirfenidone in clinical practice be-
cause it was the first anti-fibrotic available in Spain (more
than 2 years before nintedanib). In our Registry, up to 313
patients (51.5%) received treatment with pirfenidone. Des-
pite the proven effectiveness of pirfenidone [34], when re-
ceiving treatment, there is always a subgroup of patients
who experience inadequate response to therapy. Patients
who continue treatment with pirfenidone after having dis-
ease progression by month 6 of treatment have a lower
risk of FVC decline or death during the subsequent 6
months of treatment [44]. For this reason, it seems recom-
mendable to maintain the treatment with pirfenidone for,
at least, 12months. In our study 8 patients (3.5%) experi-
enced clinical worsening during the treatment with pirfe-
nidone, and 9 patients (3.9%) discontinued treatment.
This percentage of discontinuation is slightly lower than
previous studies, such as CAPACITY (7.5 and 5.8% of pa-
tients), or ASCEND (16%) [45, 46]. It is interesting to note
that in our study the median survival rate of total patients
and those receiving pirfenidone was similar (5.8 years).
Fig. 2 Mortality and survival analyze depending on gender and pirfenidone treatment. a No statistically significant higher mortality was observed
in males (HR 1.5; 95% 0.94–2.3, p = 0.092). b There was no statistically significant difference in mortality among pirfenidone treated patients depending
on gender (HR 1.6; 95% 0.86–3, p = 0.139. c Survival time (weeks) analyzed by gender and pirfenidone treatment was not statistically different
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This result is in disagreement with other studies, such as
the European Registry (EurIPFreg) which reported a sig-
nificant improvement in survival rate in patients receiving
anti-fibrotic treatment (mean 123.1months; 83% of cases
with pirfenidone and 17% with nintedanib) after 7 years of
follow-up, comparing with patients not receiving it (mean
68.3months) [24]. Although no definitive explanation can
be provided, we suppose it is because pirfenidone has
been only available to patients with FVC < 80% for a long
time in most of Spanish hospitals. This fact might have
limited the rate of survival in patients receiving
pirfenidone. Finally, DLCO at diagnosis was the only factor
significantly associated with mortality. In our study, a pa-
tient had 39.1% lower risk of death per 10 units of DLCO
(%) increased. The impact of DLCO on survival has already
been described in previous studies [47, 48]. In fact, some
indices combine DLCO together with FVC (the Gender
Age Physiology score) and with forced expiratory volume
in 1 s (the Composite Physiological Index) for predicting
mortality [49, 50].
Main limitations of our study were intrinsically related
to the retrospective nature of data collection in the first
Table 4 Demographic and clinical characteristics of patients with idiopathic pulmonary fibrosis receiving pirfenidone
N available Total
Gender (male/female), n (%) 231 184 (79.7)/ 47 (20.3)
Age mean years (SD) 231 68.9 (8.4)
Smoking habits, n (%) 231
Never-smoker 59 (25.9)
Ex-smoker 156 (68.4)
Smoker 13 (5.7)
Time from diagnosis to inclusion in the registry, mean years (SD) 231 1.7 (2.1)
Disease progression since onset of symptoms, mean months (SD) 211 22.7 (23.7)
Time of treatment with pirfenidone, mean years (SD) 231 1.5 (1.1)
FVC, mean % of predicted (SD)
At baseline 226 74.1 (15.5)
After 12 months of treatment 181 71.5 (16.7)
DLCO, mean % of predicted (SD)
At baseline 200 47.4 (16.9)
After 12 months of treatment 150 47.2 (17.6)
6-min walk distance mean m (SD)
At baseline 158 425.5 (114.7)
After 12 months of treatment 55 429.0 (117.4)
Diagnostic procedures, n (%) 231
High-resolution computed tomography 229 (99.6)
Pulmonary function test 228 (98.7)
Autoimmune serology 213 (94.2)
6-min walk test 173 (77.2)
Surgical lung biopsy 78 (34.2)
Lung cryobiopsy 14 (6.4)
Adverse events related to pirfenidone, n (%) 231 54 (23.4)
Gastrointestinal discomfort 22 (9.5)
Anorexia/weight loss 18 (7.8)
Photosensitivity 13 (5.6)
Fatigue 10 (4.3)
Dizziness 3 (1.3)
Alteration of liver enzymes 2 (0.9)
Others 9 (3.9)
SD standard deviation, FVC forced vital capacity, DLCO diffusing capacity for carbon monoxide
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participants in the Registry (those diagnosed before
2011). Presumably, no available data would improve the
knowledge in management of IPF in clinical practice.
For example, we only collected information of treat-
ments at the time of inclusion. There is thus a lack of in-
formation regarding when they actually received the
treatment or whether or not the patient received a new
treatment during the follow-up. Another limitation de-
rived from the heterogeneity of patients (including mild,
moderate and severe disease) and some uncertainty as-
sociated with the diagnostic process, i.e. integrating in-
formation from different healthcare professionals, such
as clinicians, thoracic radiologists, and pathologists; with
varying degrees of experience; and different sites (univer-
sity or non-university facilities, with or without access to
multidisciplinary team meetings) [32]. Furthermore, we
couldn’t identify those cases diagnosed based on disease
behaviour (working diagnosis), which probably could be
part of the IPF cases without lung biopsy that required
multidisciplinary discussion. In this regard, SEPAR has
recently created a registry of Spanish hospitals according
to level of ILD expertise [27]. Differences in the access
to medications among Spanish regions may also contrib-
ute to heterogeneity. Another limitation was that the
type of centre of recruitment (ILD specialist or non- ILD
specialist academic centres) may have biased the results
as ILD specialist centres could preferentially enrol
patients in clinical trials (an exclusion factor for the
present study) or prescribe antifibrotic medication. Re-
garding the 5.6% (19 male/9 female) of cases with low
titter of non-specific positive auto-antibodies, all of them
had been evaluated by an expert rheumatologist, exclud-
ing the association with connective tissue diseases. Al-
beit, only pulmonologists from ILD and non- ILD
specialist centres recruited the patients. Furthermore,
this database was not established to evaluate the safety
profile or effectiveness of pirfenidone, thus conclusions
given with reference to this should be made carefully.
Although a higher number of centres would strength re-
sults and conclusions, our cohort of patients is represen-
tative of the whole population of patients with IPF in
Spain. This valuable information can be used in subse-
quent studies to build prediction models for Spanish pa-
tients with IPF. Another goal of the study is that all
patients derived from public hospitals, having the same
(free) access to procedures and medications.
Conclusions
Demographic characteristics of patients from the
SEPAR IPF National Registry are in accordance with
other national registries. In agreement with inter-
national guidelines, the diagnosis is mainly based on
HRCT in the proper clinical context. A low percent-
age of patients require invasive procedures for the
Table 5 Main sociodemographic and clinical characteristics of patients from other National Registries
SEPAR IPF National
Registry
INSIGHTS-IPF
[17]
Finnish IPF
[18]
Swedish IPF
[19]
Indian IPF Ω
[20]
Australian IPF
[21]
EMPIRE IPF
[22]
EurIPFreg
[23]
Country Spain Germany Finland Sweden India Australia Czech part Europe b
Number of patients, n 608 502 111 71 148 647 514 525
Males, % 80.8 77.9 60.4 70.4 73.6 67.7 69.8 73.7
Age mean years 70.2 68.7 73.5 70.0 64.7 70.9 67.0 68.1
BMI mean Kg/m2 28.2 27.6 28.1 27.0 – 28.7 28.7 27.2
Ex-smoker, % 63.7 60.2 45.9 56.4 – 71.7 – 65.4
6MWD, mean m 423.5 267.6 – – 420 388
FVC, mean % of predicted 77.6 72.2 80.4 72.3 57.5 81.0 80.0 68.4
DLCO, mean % of predicted 48.5 35.5 57.3 52.1 – 48.4 45.6 42.1
Symptoms indicative of IPF at diagnosis, %
Dyspnoea 84.7 85.9 44.7 a – – – – 90.1
Inspiratory bibasilar crackles 89.6 79.0 – – – – – 95.5
Cough 62.8 74.9 46.6 a – – – – 53.2
Procedures for definitive diagnosis, %
HRCT 99.2 90.2 – 72 – – – –
Surgical lung biopsy 26.5 34.1 – 14 – – – 32→ 8 c
Multidisciplinary discussion 23.8 21.8 – 20 – – – –
a From patients with available data; b EurIPFreg, the European IPF Registry has collected information of hospitals from Germany, France, United Kingdom, Italy,
Spain, Hungary, and Czech Republic; c 32% in 2009 and 8% in 2016; Ω IPF patients are part of the interstitial lung disease registry completed in India
SD standard deviation, BMI body mass index, 6MWD 6-min walk distance, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, HRCT
high-resolution computed tomography
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definitive diagnosis. The treatment with pirfenidone
is generally safe and well tolerated, and most cases
do not present disease progression after 12 months.
Additional studies, including more patients and cen-
tres to the Registry, are required to corroborate
these results. This SEPAR IPF Registry should help
to further characterize current characteristics and fu-
ture trends of IPF patients in Spain, and compare/
pool them with other registries and cohorts.
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